Position in LLY
as of Jun 30, 2026
· filed Aug 5, 2026
Position Value
$4,514,654
+$1,952,175 QoQ
Shares Held
3,764
+35.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.80%
of 13F equity value
Holder Rank
#1,795
of 4,605 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LLY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026111 Capital holds $33,935,331 across 7 Drug Manufacturers - General names. LLY ranks #2 (13.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AZN |
Astrazeneca PLC
|
112,973 | $21,421,940 | |
| 2 | LLY |
ELI LILLY & Co
This page
|
3,764 | $4,514,654 | |
| 3 | PFE |
Pfizer Inc
|
153,909 | $3,706,128 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
15,807 | $1,997,056 | |
| 5 | AMGN |
Amgen Inc
|
3,851 | $1,394,524 | |
| 6 | MRK |
Merck & Co., Inc.
|
4,582 | $588,787 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
5,419 | $312,242 |
All Filings in LLY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,514,654 | 3,764 | Shares | Sole | 2026-08-05 | |
| 2026-03-31 | $2,562,479 | 2,786 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $2,181,600 | 2,030 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $499,002 | 654 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,183,326 | 1,518 | Shares | Sole | 2025-07-21 | |
| 2025-03-31 | $2,412,483 | 2,921 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||